Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects

NCT06363292 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Ophthalmological Agent Toxicity
Bacterial Conjunctivitis

Interventions

DRUG: PRO-231
DRUG: VIGAMOXI®

Sponsor

Laboratorios Sophia S.A de C.V.